Literature DB >> 16109652

Long-term safety of GDNF gene delivery in the retina.

Wei-Chi Wu1, Chi-Chun Lai, Show-Li Chen, Ming-Hui Sun, Xiao Xiao, Tun-Lu Chen, Ken-Kuo Lin, Shu-Wen Kuo, Yeou-Ping Tsao.   

Abstract

PURPOSE: To examine retinal function after the long-term, gene therapy-delivered expression of exogenous glial cell line-derived neurotrophic factor (GDNF).
METHODS: Forty Sprague-Dawley rats each received an intravitreal injection of recombinant adeno-associated virus expressing GDNF (rAAV-GDNF) in their right eye. The left eye was untreated. One year after viral transduction in ocular tissues, retinal morphology and function were compared between rAAV-GDNF-injected and normal naïve eyes. Synthesis and accumulation of GDNF within the retina were immunohistologically confirmed using enzyme-linked immunosorbent assay. Morphological analyses included light microscope examination of retinal sections and the counting of retinal ganglion cells. Inflammation by infiltration of leukocytes in retina was assessed immunohistochemically. Retinal function was assessed using electroretinography.
RESULTS: GDNF expression was confirmed. There was no obvious abnormality in retinal section or increased infiltration by leukocytes after retinal transduction of rAAV-GDNF for 1 year. Counts of retinal ganglion cells were not decreased in rAAV-GDNF-injected eyes. There were no statistical differences in amplitude as well as latency of the electroretinogram-determined a- and b-waves between transduced and untreated eyes.
CONCLUSIONS: Long-term expression of GDNF within the eyes can be achieved by intravitreal injection of rAAV vectors in the absence of morphological or functional deficits in the retina.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109652     DOI: 10.1080/02713680591005922

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  3 in total

1.  AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa.

Authors:  Deniz Dalkara; Kathleen D Kolstad; Karen I Guerin; Natalie V Hoffmann; Meike Visel; Ryan R Klimczak; David V Schaffer; John G Flannery
Journal:  Mol Ther       Date:  2011-04-26       Impact factor: 11.454

2.  Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats.

Authors:  Youn-Shen Bee; Shwu-Jiuan Sheu; Yi-Ling Ma; Hsiu-Chen Lin; Wen-Tsang Weng; Hsiao-Mei Kuo; Huei-Chun Hsu; Chia-Hua Tang; Jau-Cheng Liou; Ming-Hong Tai
Journal:  Mol Vis       Date:  2010-04-28       Impact factor: 2.367

Review 3.  Gene therapy in animal models of autosomal dominant retinitis pigmentosa.

Authors:  Brian Rossmiller; Haoyu Mao; Alfred S Lewin
Journal:  Mol Vis       Date:  2012-10-06       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.